Publications by authors named "Jan Fallingborg"

Claim this Profile
T
The effect of proton-pump inhibitor therapy on disease outcomes in inflammatory bowel disease: a population-based cohort study.
Thomas Deleuran, Gry Juul Poulsen, Lone Larsen, Jan Fallingborg, Peter Jepsen

Therap Adv Gastroenterol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals - a Danish register-based study of a region with 580,000 citizens.
Anne Lund Krarup, Lone Larsen, Alev Büyükuslu Nayeb, Simon Grøntved, Søren Paaske Johnsen, Jan Fallingborg

Scand J Gastroenterol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Has the Incidence of Inflammatory Bowel Disease Peaked? Evidence From the Population-Based NorDIBD Cohort 1978-2020.
Lone Larsen, Anastasia Karachalia Sandri, Jan Fallingborg, Bent Ascanius Jacobsen, Henrik Albæk Jacobsen

Am J Gastroenterol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.
Mette Julsgaard, Christian L Hvas, Richard B Gearry, Peter R Gibson, Jan Fallingborg

Inflamm Bowel Dis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment.
Lone Larsen, Tine Jess, Asbjørn M Drewes, Anders Dige, Jan Fallingborg

Eur J Gastroenterol Hepatol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine.
Robin Christensen, Berit L Heitmann, Karina Winther Andersen, Ole Haagen Nielsen, Signe Bek Sørensen, Jan Fallingborg

BMJ Open· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014.
Lone Larsen, Asbjørn Mohr Drewes, Marie Christine Hede Broberg, Jan Fallingborg, Bent Ascanius Jacobsen

Inflamm Bowel Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency.
Svein Oskar Frigstad, Anne Haaber, Antal Bajor, Jan Fallingborg, Per Hammarlund

Gastroenterol Res Pract· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease.
Mette Julsgaard, Christian L Hvas, Richard B Gearry, Thea Vestergaard, Jan Fallingborg

Inflamm Bowel Dis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.
Vibeke Andersen, Uffe Holmskov, Signe Bek Sørensen, Mohamad Jawhara, Karina W Andersen, Jan Fallingborg

Nutrients· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Touch screens as a tool in patient care in the IBD outpatient clinic.
Lone Larsen, Asbjørn Mohr Drewes, Jan Fallingborg, Bent Ascanius Jacobsen, Tine Jess

Scand J Gastroenterol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Mette Julsgaard, Lisbet A Christensen, Peter R Gibson, Richard B Gearry, Jan Fallingborg

Gastroenterology· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
Casper Steenholdt, Jørn Brynskov, Ole Ø Thomsen, Lars K Munck, Jan Fallingborg

Dig Dis Sci· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease.
Claus Aalykke, Michael Dam Jensen, Jan Fallingborg, Tine Jess, Ebbe Langholz

Dan Med J· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg

Gut· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study.
Tine Jess, Erzsébet Horváth-Puhó, Jan Fallingborg, Henrik H Rasmussen, Bent A Jacobsen

Am J Gastroenterol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologic therapy in inflammatory bowel disease.
Klaus Theede, Jens Frederik Dahlerup, Jan Fallingborg, Christian Lodberg Hvas, Jens Kjeldsen

Dan Med J· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budesonide treatment and expression of inducible nitric oxide synthase mRNA in colonic mucosa in collagenous colitis.
Ole K Bonderup, Jesper B Hansen, Poul Madsen, Vibeke Vestergaard, Jan Fallingborg

Eur J Gastroenterol Hepatol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002.
Bent A Jacobsen, Jan Fallingborg, Henrik H Rasmussen, Karí R Nielsen, Asbjørn M Drewes

Eur J Gastroenterol Hepatol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
Jan F Fallingborg

Ugeskr Laeger· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Mesalazine is effective in Crohn disease 1].
Jan Fallingborg, Ebbe Langholz, Lisbet Ambrosius Christensen, Pia Munkholm, Jens Frederik Dahlerup

Ugeskr Laeger· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis